LENZ

Over the past six months, LENZ Therapeutics' stock price has declined by 54.91%. Key events include the Q4 2025 earnings report, which showed $1.6 million in product revenue from VIZZ but was considered disappointing, leading to an 18% drop in shares. Analyst rating adjustments followed the Q4 results, with H.C. Wainwright and Citi lowering their price targets. The FDA assigned a PDUFA target action date of August 8, 2025, for LNZ100, and the company announced plans to expand its sales organization.